Research Update:

In September 2024, the International Society for Frontotemporal Dementias (ISFTD) Conference in Amsterdam brought together global experts to discuss the latest advancements in FTD research.

The Power of Patient Voices

The conference opened with a moving keynote by Emma Heming Willis, a caregiver, who emphasised the importance of early diagnosis and the role of research in improving the lives of those with FTD. Her message underscored the need for research that reflects the real-world experiences of patients and their families.

Advancing Diversity in FTD Research

One of the key conference themes was improving diversity in FTD research to better serve individuals from various linguistic and cultural backgrounds.

• Language-Specific Research: Dr. Yuichi Higashiyama highlighted differences in how FTD affects Japanese and English speakers with Primary Progressive Aphasia (PPA), demonstrating that speech-related brain atrophy manifests differently across languages.
• Bilingualism and Cognitive Resilience: Studies show that bilingual individuals may experience a delay in symptom onset by over eight years, suggesting that language diversity contributes to cognitive resilience.
• Cultural Context in Diagnosis: Professor Suvarna Alladi introduced the Dementia Design Studio, a clinic that uses real-world tasks like cooking and packing to differentiate between FTD and Alzheimer’s, offering a more accurate and culturally relevant approach to diagnosis.

Clinical Trials: A Growing Field of Hope

Exciting advancements in clinical trials were another highlight:

• Platform Trials: These innovative trials allow multiple therapies to be tested simultaneously, significantly reducing the time, cost, and participants needed.
• At-Home Assessments: To overcome barriers like travel costs, researchers are exploring remote data collection, enabling broader participation.

Some promising therapies discussed included:

• Latozinemab (Phase 3): A treatment targeting progranulin protein regulation.
• Gene Therapy Candidates: Including PBFT02 and AVB-101, aimed at treating genetic forms of FTD.
• Non-Drug Therapies: Speech-based interventions like the Communication Bridge trial for PPA patients.

Genetic Breakthroughs and Biomarker Development

Researchers also unveiled new genetic risk factors:

• Professor Rosa Rademakers identified a novel risk variant on chromosome 15 associated with the rare FTD subtype FTD-U, characterised by psychiatric symptoms.
• Advances in MRI biomarkers and deep learning technologies were highlighted as tools to improve diagnostic accuracy and better differentiate between FTD subtypes.

Compassionate Home Care for Individuals with Frontotemporal Dementia

At Care at Home Midlands, we understand the unique challenges faced by individuals with Frontotemporal Dementia (FTD). Our client-centred approach prioritises listening to clients and their families to create personalised care plans that address their specific needs. Our highly trained carers bring expertise and compassion to support individuals with dementia-related conditions, ensuring safety, dignity, and comfort. With flexible service options, we offer both short-term and long-term home care solutions designed to fit seamlessly into each client’s lifestyle, providing peace of mind and enhanced quality of life.